

14th February 2024

To,
The Corporate Relations Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.

Dear Sir/Madam,

Sub: Outcome of Board Meeting under Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH

We hereby inform you that the Board of Directors of the Company at its just concluded meeting has, inter-alia, transacted the following items of business:

- 1. Approved the Un-Audited financial results for the Third Quarter and Nine Months ended on 31st December, 2023.
- 2. Took note of the Limited Review Report on Un-Audited financial results for the Third quarter and Nine Months ended on 31st December, 2023 issued by the Statutory Auditors of the Company.
- 3. Approved appointment of Mr. Sanagari Kondal Reddy (Din: 02530466) as Additional Director in the Non-Executive Independent Category of the Company.

The Board of Directors based on the recommendation of Nomination and Remuneration Committee have appointed Mr. Sanagari Kondal Reddy (Din: 02530466) as an Additional Director of the Company in the category of an Independent Director (Non-Executive) w.e.f. 14th February, 2024 for a term of up to 5 (five) consecutive years subject to approval by the Shareholders of the Company.

The Details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A to this letter, the contents of which are self-explanatory.



The meeting commenced at 04.00 P.M. and concluded at 05.00 P.M.

This is for your information and necessary records.

Thanking you,

Yours faithfully,

Oxygenta Pharmaceutical Limited

(Formerly known as S.S. Organics Ltd.)

Name: Sai Sudhakar Vankineni Designation: Managing Director

DIN.: 00733001



Annexure A

The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015 for appointment of Directors:

Appointment of Mr. Sanagari Kondal Reddy (Din: 02530466) as Additional Director in the Non-Executive Independent Category of The Company:

Sr.No	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. Sanagari Kondal Reddy (Din: 02530466) as an Additional Director of the Company in the Independent category.
2	Date of appointment /cessation (as applicable) & term of appointment.	Mr. Sanagari Kondal Reddy (Din: 02530466) has been appointed as an Additional Director of the Company in the Independent category on the Board of the Company w.e.f. 14 th February 2023, for the period of 5 years subject to approval of the members of the company.
3	Brief Profile	Mr. Sanagari Kondal Reddy (Din: 02530466), Aged 47 years and has been working in Pharma Industry for more than 15 years and having very well knowledge in the field.
4	Disclosure of relationships between directors	None of the directors of the company are related to Mr. Sanagari Kondal Reddy.
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19	He is not debarred from holding the office of the director by virtue of any SEBI Order or any other statutory authority.